



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : CRIPPS et al. Confirmation No: 1830
Appl. No. : 10/774,393
Filed : February 10, 2004
Title : PHARMACEUTICAL FORMULATION OF FLUTICASONE
: PROPIONATE

TC/A.U. : 1616
Examiner : M Haghighatian

Docket No.: : CRIP3001C3/REF
Customer No: : 23364

REQUEST FOR RECONSIDERATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Official Action of March 27, 2006, in connection with the above-identified application. The period for response to this Official Action has been extended to expire on August 27, 2006, by the filing herewith of a Petition for a Two month extension of time and payment of the required fee.

Applicants acknowledge with appreciation the courtesy of the interview extended the undersigned attorney by Examiner Haghighatian, the examiner in charge of this application and her supervisor, Mr. Richter. As reflected on the interview summary form, an agreement was reached and that all of the claims will be allowed upon filing a request for reconsideration. In addition, a terminal disclaimer will be filed once the provisional nature of the obviousness double patenting rejections are removed.

In addition, it is noted that the claims had been previously allowed and it is believed that the additional prior art does not render obvious the claimed subject matter. The claims in the application have been reviewed and it is most respectfully submitted that all of the claims now present in the application are in full compliance with 35 USC 112 and are clearly patentable over the prior art of record as would be appreciated by one of ordinary skill in the art to which the invention pertains as discussed at the interview, for reasons already of record and for the following reasons.